GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (STU:1U5) » Definitions » Debt-to-Asset

WAVE Life Sciences (STU:1U5) Debt-to-Asset : 0.07 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is WAVE Life Sciences Debt-to-Asset?

WAVE Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €7.3 Mil. WAVE Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €17.0 Mil. WAVE Life Sciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was €336.4 Mil. WAVE Life Sciences's debt to asset for the quarter that ended in Dec. 2024 was 0.07.

WAVE Life Sciences Debt-to-Asset Historical Data

The historical data trend for WAVE Life Sciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences Debt-to-Asset Chart

WAVE Life Sciences Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.15 0.26 0.12 0.07

WAVE Life Sciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.13 0.14 0.08 0.07

Competitive Comparison of WAVE Life Sciences's Debt-to-Asset

For the Biotechnology subindustry, WAVE Life Sciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WAVE Life Sciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where WAVE Life Sciences's Debt-to-Asset falls into.


;
;

WAVE Life Sciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

WAVE Life Sciences's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(7.294 + 16.967) / 336.358
=0.07

WAVE Life Sciences's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(7.294 + 16.967) / 336.358
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WAVE Life Sciences  (STU:1U5) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

WAVE Life Sciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of WAVE Life Sciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

WAVE Life Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (STU:1U5) » Definitions » Debt-to-Asset
Comparable Companies
MDXG ETNB NVAX XFOR VRDN AUPH INVA SNDX PHVS IOVA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
WVE:USA 1U5:Germany
Address
7 Straits View No. 12-00, Marina One East Tower, Singapore, SGP, 018936
Website
https://www.wavelifesciences.com
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

WAVE Life Sciences Headlines

No Headlines